DE2559384A1 - Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics - Google Patents

Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics

Info

Publication number
DE2559384A1
DE2559384A1 DE19752559384 DE2559384A DE2559384A1 DE 2559384 A1 DE2559384 A1 DE 2559384A1 DE 19752559384 DE19752559384 DE 19752559384 DE 2559384 A DE2559384 A DE 2559384A DE 2559384 A1 DE2559384 A1 DE 2559384A1
Authority
DE
Germany
Prior art keywords
caffeine
nicotinic acid
acid amide
nicotinamide
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19752559384
Other languages
German (de)
Inventor
Josef Dipl Chem Dr Rer N Klosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19752559384 priority Critical patent/DE2559384A1/en
Publication of DE2559384A1 publication Critical patent/DE2559384A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12H—PASTEURISATION, STERILISATION, PRESERVATION, PURIFICATION, CLARIFICATION OR AGEING OF ALCOHOLIC BEVERAGES; METHODS FOR ALTERING THE ALCOHOL CONTENT OF FERMENTED SOLUTIONS OR ALCOHOLIC BEVERAGES
    • C12H1/00—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages
    • C12H1/12—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages without precipitation
    • C12H1/14—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages without precipitation with non-precipitating compounds, e.g. sulfiting; Sequestration, e.g. with chelate-producing compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinations of caffeine (I) with nicotinamide (II) are new. The amt. of (II) is pref. sufficient to make (I) at least partially soluble in water. Esp. the wt. ratio (I):(II) is 1:0.1-5. The combinations may be used in medicaments (for human and veterinary use), diatetics, foods, condiments and cosmetics. They may be incorporated into cold drinks, wines, fruit-juice, sweets, etc. Presence of (II) renders (I) soluble in water at neutral pH and gives a controlled-release effect. Toxicity is reduced and side-effects (e.g. on the heart, stomach and intestines are reduced. In an example, capsules are filled with a mixt. of 50 mg (I), 100 mg (II) and 200 mg lactose and additives.

Description

Coffein-Kombination Caffeine combination

Die Erfindung umfaßt eine Coffein-Kombination aus Coffein und Nikotinsäureamid.The invention includes a caffeine combination of caffeine and nicotinic acid amide.

Coffein ist bereits mit zahlreichen anderen Substanzen kombiniert worden, so insbesondere mit Schmerzstillungsmitteln und mit kreislaufaktiven. Nun haben alle diese Kombinationen keinen Einfluß auf die physikalischen oder biochemischen Eigenschften des Coffeins bewirkt. Coffein sollte in all den bisher bekannzen Kombinationen zunächst nur die Wirkung bekannter Schmerzstillungs- oder Kreislaufmittel verbessern, rnehr nicht. Vor allem wurde ei all den Kombinationen niemals eine Verbesserung der physikalischen oder gar phar kologischen Eigenschaften des Coffeins erstrebt.Caffeine is already combined with numerous other substances especially with pain relievers and active circulatory drugs. so none of these combinations have any influence on the physical or biochemical Caffeine's properties. Caffeine should be used in all of the previously known combinations initially only improve the effect of known pain relievers or circulatory drugs, no more. Above all, none of the combinations was ever an improvement strives for the physical or even pharmaceutical properties of caffeine.

Demgemäß wurde gefunden, daß eine Kombination des Coffeins mit Nikotinsäureamid 1. eine Löslichkeit des Coffoins in Wasser mit neutralem pH bewirkt, eine Verbesserung der pharmakologischen Eijenschaften des Coffeins ergibt. insbesondere ergibt sich durch die Kombination ein leistungssteigernder Effekt, wie ein solcher bei geringer Toxizität von keinem bisher bekannten Stoff gegeben wird.Accordingly, it has been found that a combination of the caffeine with nicotinic acid amide 1. A solubility of the coffoin in water with neutral pH causes an improvement the pharmacological properties of caffeine. in particular it results through the combination, a performance-enhancing effect, such as one with low Toxicity is not given by any previously known substance.

Für die Kombinution eignen sich Mischverhältnisse von einem Teil Coffein auf 0,1 bis 5 Teile Nikotinsäureamid, zweckmäßig jedoch : 1, also ein Teil Coffein und ein Teil hsikotinsqureamid.Mixing ratios of one part of caffeine are suitable for the combination to 0.1 to 5 parts of nicotinic acid amide, expediently however: 1, that is to say one part of caffeine and part of hsikotinsqureamid.

Erfindungsgemäß soll aber diese Kombination durch Mischungsgrenzen nicht begrenzt werden. Demgemaß ist Gegenstand der Erfindung Präparate, welche Coffein und Nikotinsäureamid besitzen. Es können einer solchen Kombination noch Alalgetika, Kreislaufmittel, Vitamine oder Traubenzucker, Lezithin und ähnliche Stoffe zugesetzt werden. Die Kombination kann in Erfindungsgetränken, Weinen, Fruchtsäften, E3onbon und dergleichen angewendet und in konventioneller weise zubereitet werden.According to the invention, however, this combination should be limited by mixing limits not be limited. Accordingly, the invention relates to preparations which contain caffeine and nicotinic acid amide. Such a combination can also contain alalgesics, Circulatory drugs, vitamins or glucose, lecithin and similar substances added will. The combination can be used in invention drinks, wines, fruit juices, candy and the like applied and prepared in a conventional manner will.

In dieser Rinsicht obliegt der Erfindung keine begrenzung.In this regard, the invention is not limited.

Die Oberlegenheit und Reuigkeit der Erfindung zeigt sich un folgenden experimenten: @@gr @@@zen und 10 gr Nikotinsäureamid werden gut gemischt, dem für @ ml Wasser hinzu, erwärmt kurz und erhalt eine klare Lösungs anlichniges Coffein ist nicht wasserlöslich, was wie folgt gezeizeight wird: 10 gr Coffein werden mit 0 ml Wasser versetzt, Man erhält eine Suspension, die auch beim Erwärmen nicht in Lösung geht.The superiority and repentance of the invention are shown in the following Experiments: @@ gr @@@ zen and 10 gr nicotinic acid amide are mixed well for Add @ ml of water, heat briefly and obtain a clear solution of similar caffeine is not soluble in water, which is shown as follows: 10 grams of caffeine are added 0 ml of water are added. A suspension is obtained which, even when heated, does not turn into Solution works.

Nun fügt man nach Erkalten portionsweise 10 gr Nikotinsäureamid hinzu. Bei einem jedoch Zusatz von Nikotinsäureamid löst sich Coffein teilweise auf. Die Lösung ist bei 5-6 gr Nikotinsaureamid vollständig.Now, after cooling, 10 g of nicotinic acid amide are added in portions. However, when nicotinic acid amide is added, caffeine partially dissolves. the Solution is complete at 5-6 grams of nicotinic acid amide.

Mit einer Mischung aus einem Teil Coffein und einem Teil Nikotinsaureamid wurden folgenden Tierversuche durchgeführt: a) akute Toxizität in mg/kg Maus Substanz DL50 in mg/kg Maus oral intravenös Coffein 285 166 Coffein-Nikotinsäure- 1700 900 amid b) krämpfe 12 mg/kg Coffein steigern die Pentetrazol-Krampfe bei Mäusen, Coffein-Nikotinsäureamid aber erst bei 80 mg/kg c) Lernleistung nach H. Rahmann (Pflügers Archiv, Bd.276, 384-397 (1962) - Versuchstiere Soldhamster.The following animal experiments were carried out with a mixture of one part caffeine and one part nicotinic acid amide: a) acute toxicity in mg / kg mouse Substance DL50 in mg / kg mouse orally intravenous Caffeine 285 166 Caffeine Nicotinic Acid- 1700 900 amide b) cramps 12 mg / kg caffeine increase the pentetrazole cramps in mice, but caffeine nicotinic acid amide only at 80 mg / kg c) learning performance according to H. Rahmann (Pflügers Archive, Vol. 276, 384-397 (1962) - experimental animals soldhamster .

Coffein stelgert in einer Besis von 5 mg/kg die Lernleistung nur um 12 gr, Coffein-Nikotinsäureamid jedoch um 65 gr. At a level of 5 mg / kg, caffeine only increases learning performance around 12 gr, but caffeine nicotinic acid amide around 65 gr.

d) Einfluß auf Herz- und Kreislauf.d) Influence on the cardiovascular system.

Coffein hat in einer dosis von 2,5 bis 10 mg/kg Hund einen Biphasischen Einfluß auf Blutdruck. Es kommt zuerst zu einem Blutdruckanstieg, dann zu einem Abfell. Caffeine is biphasic at a dose of 2.5 to 10 mg / kg dog Influence on blood pressure. There is an increase in blood pressure first, then one Abfell.

Coffein-Nikotinsäureamid hat in Dosen von 1,5 bis 30 mg/kg Hund ke@@ Ein@fin auf Blutdurck.Caffeine nicotinic acid amide has doses of 1.5 to 30 mg / kg dog ke @@ An @ fin on blood pressure.

@ise folgensche Wirkung der neuen Kombination war in keiner weise vorherzusehen gewesen. Im Gegenteil, bei der bekannten unangenehmen Wirkung des Coffeins auf Herz, Magen und Darm war bei einer Wesserlöslichmachung und einer jeden Kombination, die Wasserlöslichkeit bewirken könnte, mit den bekannten Herzsensaionen und Hitzewalliungen zu rechnen. Solche traten auch beim Menschen in Versuchen emnach ergibt die Kombination Coffein-Nikotinsäureamid ein Arzneimittel mit einer nicht zu erwartenden Wirkung einerseits und einem Fortschritt, wie ein solcher nicht zu erwarten gewesen ist.The following effect of the new combination could not have been foreseen in any way. On the contrary, with the well-known unpleasant effects of caffeine on the heart, stomach and intestines, the well-known cardiac sensations and hot flashes were to be expected with water-solubilization and any combination that could cause water-solubility. Such tests have also occurred in humans Accordingly, the combination of caffeine-nicotinic acid amide results in a medicament with an unexpected effect on the one hand and a progress that could not have been expected.

Diese Kombination soll als Arzneimittel in der Haman- und Veterinärmedizin, in der und Nachrungsmittelindustrie in konventionell bekannten Zubereitungen Anwendung finden.This combination is intended as a medicinal product in Haman and veterinary medicine, in the and food industry are used in conventionally known preparations.

demnach ist das wesen der Erfindung: Arzneimittel, Diätetika, Nahrungs- und Gehubmittel, kosmetische Mittel, die Nikotinsäureamid und Coffein in solchen Verhältnissen enthalten, daß die Kombination vollständig oder teilweise wasserlöslich ist.Accordingly, the essence of the invention is: Medicines, dietetics, nutritional and sweeteners, cosmetic agents that contain nicotinic acid amide and caffeine in such Contains proportions that the combination is completely or partially water-soluble is.

Es soll an einigen beispielen die Ausführung der Erfindung gezeigt werden, ohne daß dieselben in den Grundgedanken eingeschränkt wird.The implementation of the invention is intended to be shown by means of a few examples without their basic ideas being restricted.

Beispiel 1: 10 gr Coffein und 10 gr Nikotinsäureamid werden miteinander gemischt.Example 1: 10 grams of caffeine and 10 grams of nicotinic acid amide are mixed together mixed.

1 gr des Gemisches sind mit @ ml Wasser glatt löslich, pH 6,7 bis 7.1 gr of the mixture is readily soluble with @ ml of water, pH 6.7 to 7th

Diese Lösung kann für Injektionszubereitungen dienen, mit Fruchtsäften, Sirupen oder Getranken verdünnt werden oder als Limonaden zubereitet werden.This solution can be used for injection preparations, with fruit juices, Syrups or beverages can be diluted or prepared as lemonades.

Beispiel 2: Tabletten Coffein 25 mg Nikotinsäureamid 25 mg Lactose 198 mg Getreidestärke 25 mg Talk 15 mg Magnesiumstearat 1 mg 290 mg Die bestandteile werden in bekannter Weise und i-rozedur zu Tabletten verarbeitet.Example 2: tablets caffeine 25 mg nicotinic acid amide 25 mg lactose 198 mg corn starch 25 mg talc 15 mg magnesium stearate 1 mg 290 mg the ingredients are processed into tablets in a known manner and procedure.

Beispiel 3: Kapseln Coffein 50 m Nikotinsäureamid 100 mg Lactose und Zusätze 200 mg Die Bestandteile werden gemischt und in Kapseln gefüllt.Example 3: Capsules caffeine 50 m nicotinic acid amide 100 mg lactose and Additions 200 mg The ingredients are mixed and filled into capsules.

Claims (1)

P a n t e n t a n s p r ü c h e Coffein-kombination, dadurch gekennzeichnet: 1. das Coffein mit Nikotinsäureamid gemischt wird; 2. gemäß Anspruch 1, dadurch gekennzeichnet, daß dem Coffein sowohl Nikotinsäureamid zugemischt wird, daß mindestens eine teilweise Auflösung des Coffeins in Wasser bis zur Vollständigkeit eintritt; 3. gemäß Ansprüch 1 und 2, dadurch gekennzeichnet, daß auf ein Teil Coffein 1 bis 3 Teile Nikotinsäureamid kommen können; Arzneimittel, Diätetika, Nahrungs- und Genußmittel, welche neben Coffein Nikotinsäureamid gemäß Anspruch 1 bis 3 enthalten. P a n t e n t a n s p r ü c h e Caffeine combination, characterized by: 1. the caffeine is mixed with nicotinic acid amide; 2. according to claim 1, characterized characterized in that both nicotinic acid amide is mixed with the caffeine, that at least a partial dissolution of the caffeine in water occurs until it is complete; 3. according to claims 1 and 2, characterized in that a portion of caffeine 1 to 3 parts of nicotinic acid amide can come; Medicines, dietetics, food and luxury items, which contain, in addition to caffeine, nicotinic acid amide according to Claims 1 to 3.
DE19752559384 1975-12-31 1975-12-31 Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics Withdrawn DE2559384A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19752559384 DE2559384A1 (en) 1975-12-31 1975-12-31 Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752559384 DE2559384A1 (en) 1975-12-31 1975-12-31 Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics

Publications (1)

Publication Number Publication Date
DE2559384A1 true DE2559384A1 (en) 1977-07-14

Family

ID=5965992

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19752559384 Withdrawn DE2559384A1 (en) 1975-12-31 1975-12-31 Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics

Country Status (1)

Country Link
DE (1) DE2559384A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833147A (en) * 1986-03-17 1989-05-23 Henkel Kommanditgesellschaft Auf Aktien Sebosuppressive compositions and method for suppressing sebaceous gland activity
DE3390114C2 (en) * 1982-07-22 1990-07-05 Richardson Vicks Inc
GB2285578A (en) * 1993-12-22 1995-07-19 Leilani Lea Beverages containing added guaranine
US5900416A (en) * 1996-02-01 1999-05-04 Anthea Enterprises Incorporated Aqueous caffeine dosage forms
US6290994B1 (en) 1995-04-12 2001-09-18 Decox, S.L. Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
WO2018001899A1 (en) * 2016-06-30 2018-01-04 L'oreal Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3390114C2 (en) * 1982-07-22 1990-07-05 Richardson Vicks Inc
US4833147A (en) * 1986-03-17 1989-05-23 Henkel Kommanditgesellschaft Auf Aktien Sebosuppressive compositions and method for suppressing sebaceous gland activity
GB2285578A (en) * 1993-12-22 1995-07-19 Leilani Lea Beverages containing added guaranine
US6290994B1 (en) 1995-04-12 2001-09-18 Decox, S.L. Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
US5900416A (en) * 1996-02-01 1999-05-04 Anthea Enterprises Incorporated Aqueous caffeine dosage forms
WO2018001899A1 (en) * 2016-06-30 2018-01-04 L'oreal Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound
FR3053334A1 (en) * 2016-06-30 2018-01-05 L'oreal LIQUID MIXTURE CONTAINING 4- (3-ETHOXY-4-HYDROXYPHENYL) BUTAN-2-ONE AND XANTHINE COMPOUND
CN109414383A (en) * 2016-06-30 2019-03-01 莱雅公司 Liquid mixture containing 4- (3- ethyoxyl -4- hydroxyphenyl) butyl- 2- ketone and Xanthine compounds
US10813865B2 (en) 2016-06-30 2020-10-27 L'oreal Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound
CN109414383B (en) * 2016-06-30 2021-12-14 莱雅公司 Liquid mixture containing 4- (3-ethoxy-4-hydroxyphenyl) butan-2-one and xanthine compound

Similar Documents

Publication Publication Date Title
DE69731467T2 (en) PROCESS FOR MAINTAINING EXISTING BODY FAT CONTENT AND / OR BODY WEIGHT
DE2521815C3 (en) Diet food preparations and mixtures and processes for their manufacture
DE69630694T2 (en) NEUTRALIZATION OF ACID FOOD AND MEDICINAL PRODUCTS
DE3151245C2 (en)
DE2813480A1 (en) MEDICINAL DEPOT PREPARATION OF THE MULTI-UNIT DOSE TYPE
DE60008127T2 (en) HIGH LIPID DIET
DE2950463A1 (en) BALINE ACID CONTAINING PHARMACEUTICAL PREPARATION WITH EXTENDED EFFECT
DE2841668A1 (en) MEDICATED ANIMAL FEED BASED ON LIVER FLOUR
DE60107272T2 (en) IRON COMPOUNDS
CH677880A5 (en)
DE3348164C2 (en)
DE69721497T2 (en) MULTIFUNCTIONAL FORMULATION FOR FAT ABSORPTION AND FOR REDUCING THE CHOLESTEROL CONTENT IN THE BLOOD, WHICH CONTAINS CHITOSAN AND NICOTINIC ACID
DE60133781T2 (en) ORAL PREPARATIONS WITH JEWELRY LIGHTER OR ANTIPRURITIC EFFECT
DE2559384A1 (en) Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics
DE10060750A1 (en) Food supplement product for intestinal activation
DE2921852A1 (en) LIPID LOWERING AGENT
DE2111638C2 (en) Prophylactic treatment of iron deficiency in piglets
DE3301328A1 (en) PRELIMINARY MEDICINAL CONTROL OF ACUTE OR CHRONIC, MYELOGENIC LEUKAEMIA
DE3833458C1 (en)
DE2528460A1 (en) 1-Carbamoyl 2-cyano aziridine as immunostimulant - for therapy of bacterial and viral infections
DE2349186C2 (en) Medicines to improve cell respiration, heart muscle performance and brain function
DE1717100A1 (en) Process for the production of anti-carcinomatous preparations of haemolytic streptococci
DE3410850A1 (en) MEDICINAL PRODUCTS FOR REINFORCING AND USING BLOOD VESSELS
DE2951132C2 (en)
DE4335441A1 (en) Preventive medical composition for the human cardiovascular system

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee